Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 8/20 | 0.42 |
| ▸ | RXRA | P19793 | 6/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 5/20 | 0.36 |
| ▸ | RARA | P10276 | 4/20 | 0.36 |
| ▸ | RARG | P13631 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086469 | 0.92 | RXRA (0.43) | HNF4ARXRARARBRARARARG | |
| SCHEMBL6085525 | 0.91 | KMT2A (0.38) | MAPTTHRBRAB9ASMN1; SMN2TSHR | |
| SCHEMBL6086318 | 0.90 | POLB (0.44) | RXRAPOLBMAPTTHRBRARB | |
| SCHEMBL6086195 | 0.88 | RXRA (0.38) | HNF4ARXRAPOLBMAPTTHRB | |
| SCHEMBL6087287 | 0.85 | SCN5A (0.39) | HNF4ARXRAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6085508 | 0.84 | PPIA (0.41) | POLBMAPTTHRBSMN1; SMN2 | |
| SCHEMBL6089239 | 0.83 | HNF4A (0.45) | HNF4ARXRASSTR5POLBMAPT | |
| SCHEMBL6085813 | 0.82 | MAPT (0.35) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6086645 | 0.78 | POLB (0.46) | RXRAPOLBMAPTTHRBRARB | |
| SCHEMBL6089231 | 0.76 | RXRA (0.47) | HNF4ARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026487-B2 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity | ALLERGAN, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | BEARD RICHARD L (US) | 2004-05-20 | — | — | US | disclosed |
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | ALLERGAN SALES, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6613917-B1 | Retinoid agonist, antagonist or negative hormone-like biological activity | ALLERGAN, INC. | 2003-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | HNF4A 157/4885RXRA 13/4885SSTR5 523/4885 |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | HNF4A 157/4885RXRA 13/4885SSTR5 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.